Method of assaying for alzheimer's disease
AssigneeThe University of Melbourne
InventorsColin Louis Masters, Ashley Ian Bush, Konrad Traugott Beyreuther
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of assaying for Alzheimer's disease in a human by determining the relative abundance of one or more forms of amyloid precursor protein (APP) or the enzyme responsible for said forms in circulatory fluid and to a method for treating the disease by modulating divalent cation, trivalent cation and/or heparin interaction with APP.
Claims3
A method of assaying for probable Alzheimer's disease in a human which comprises determining in a sample of human circulatory fluid the amount of at least one of the 130 kDa form or 42 kDa form of amyloid precursor protein (APP) in said sample, wherein said APP is detected by Western blot with antibodies specific for at least one of the 130 kDa form or 42 kDa form of APP, comparing the levels of at least one of the 42 kDa form or the 130 kDa form in said sample to a normal control and correlating a significant increase in the 130 kDa form or a significant decrease in the 42 kDa form with the presence of Alzheimer's disease, wherein said 130 kDa form and 42 kDa form specifically binds to antibody 22C11.
Dependencies are inferred from the claim text.